Help
DTI
journal
Journal newsletter sent to subscribers in week 37, 2009. Follow link to see newsletter summary. Register to receive newsletters.
The Editor in Chief has issued a new call for papers. Read it here.
The journal has been accepted for indexing in EBSCO Academic Search Complete.
Aims and scope:
Drug Target Insights covers current developments in all areas of the field of clinical therapeutics. The journal has two specific areas of focus:
Drug Target Insights seeks to be the most up-to-date journal for those who need to be informed of the latest and most important developments in the field. The journal seeks to be the most reliable and up-to-date journal in this field by offering rapid and credible pre-production submission processing to authors. By publishing in open-access format, authors are able to communicate with the widest possible group of readers.
Editorial standards and procedures:
Submissions, excluding editorials, letters to the editor and dedications, will be peer reviewed by two reviewers. Reviewers are required to provide fair, balanced and constructive reports.
Under our Fairness in Peer Review Policy authors may appeal against reviewers' recommendations which are ill-founded, unobjective or unfair. Appeals are considered by the Editor in Chief or Associate Editor.
Papers are not sent to peer reviewers following submission of a revised manuscript. Editorial decisions on re-submitted papers are based on the author's response to the initial peer review report.
Indexing:
This journal is indexed by the following services:
SPARC Europe Seal award winner:
This journal has been awarded a SPARC Europe Seal. The Seal is an initiative of SPARC Europe (Scholarly Publishing and Academic Resources Coalition) and the Directory of Open Access Journals (DOAJ) which is awarded to journals applying a Creative Commons CC-BY copyright license and that make journal metadata accessible to DOAJ.
Amongst other important services DOAJ makes metadata OAI-compliant. This in turn enhances the visibility of papers and allows OAI-harvesters to include the details of journal articles in their services. We encourage readers to make use of this valuable resource. The DOAJ search page is available here.
National Institutes of Health Public Access Policy compliant:
As of April 7 2008, the US NIH Public Access Policy requires that all peer reviewed articles resulting from research carried out with NIH funding be deposited in the Pubmed Central archive.
If you are an NIH employee or grantee Libertas Academica will ensure that you comply with the policy by depositing your paper at Pubmed Central on your behalf.
Call for papers:
Read the Editor in Chief's latest call for papers here.
Submission types accepted:
Submissions of the following types of manuscripts are accepted:
All submissions are subject to prompt, objective and fair peer review in compliance with our Fairness in Peer Review Policy. Copyright in published articles remains with the author(s). Authors are continually informed of the progress of their paper and our staff are friendly and responsive.
One author recently wrote: "I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely."
Criteria for publication:
Publication is dependent on peer reviewers' judgement of papers. Reviewers are asked to provide thoughtful and unbiased feedback to authors to ensure that the conclusions of papers are valid and manuscripts achieve reasonable standards of scholarliness and intelligibility.
Previous work in the field must be acknowledged and papers should read without unreasonable difficulty. Papers should fit comfortably within the scope of the journal.
Reviewers are asked to act in a fair, objective and constructive manner which maintains quality standards and helps authors to communicate their research. They are instructed that in areas of genuinely novel research issues may be raised which cannot immediately be resolved and that absolutely rigorous validation of data may therefore not be possible.
More information on the role of peer reviewers is available on the information for reviewers page. Where authors consider that reviewers have made recommendations which are unreasonable, unobjective or ill-founded they may appeal them to the Editor in Chief or Associate Editor under our Fairness in Peer Review Policy.
Articles submitted to other journals:
We are willing to consider papers which have been peer reviewed by other journals but not accepted for publication.
Services for authors:
Prior to peer review of your paper we can:
After peer review of your paper we can:
What other authors have said:
Libertas Academica actively requests, receives and acts upon feedback from authors, readers and editorial boards. Here's what some recent authors have said about us:
"Within a couple of days the reviewers had been procured and the manuscript was out."
"The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I've never had such complete communication with a journal."
"LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought."
Article processing fees:
All submissions to this journal are subject to an article processing fee if they are accepted for publication. Article processing fees are used to fund the processing of your paper and development of the journal. Article processing fees are the only compulsory charge you will face and do not vary according to word count, page count, colour figures or any other factor. There is no additional charge for the author(s) to make any use of their article and no charge to readers to access it.
Full fee waivers are available for authors working in undeveloped nations and partial discounts of 20-50% are available to authors in other nations. Authors must be able to verifiably demonstrate their suitability for a discount or waiver. Availability of waivers and discounts is subject to monthly availability and is given at the publisher's discretion. Waivers and discounts must be applied for prior to submission. Neither are available after submission.
Register as a peer reviewer:
Do you wish to register as a peer reviewer? Or are you already a registered peer reviewer but you need to update your contact details? To register or update your details visit the peer reviewer registration form.
Applicants must be able to demonstrate at least five years of continuous experience in the journal's subject area including at least two in the previous 24 months.
Dr. Monica Milani is a Research Associate in the Medicine Department at the University of Minnesota. Currently, her research interest is focused on the elucidation of the mechanisms of cancer growth inhibition by HIV protease inhibitors. She is also involved in projects aimed at clarifying the role of epoxyeicosatrienoic acids in breast cancer progression.
Previously, Dr. Milani had worked in the Department of Biochemistry at the University of Minnesota and at the Neurological Institute “Carlo Besta” in Milan (Italy), where she was conducting research on the autoimmune disorder Myasthenia Gravis. For three years she was the principal investigator of a Muscular Dystrophy Association research grant. She has served as reviewer for the “Cellular Immunology” journal, and is coauthor of several papers, review articles, and book chapters. She has attended and presented her work at several international conferences.
>> Dr Milani's latest call for papers
Julie Andrews, PhD
The University of Manchester, Manchester, UK
John N van den Anker, PhD
Children's National Medical Center/Children's Research Institute, Washington, DC, USA
Marianna K Baum, PhD
Florida International University, Miami, FL, USA
Alexander M Cole, PhD
University of Central Florida, Orlando, FL, USA
Andrew Coop, PhD
University of Maryland, Baltimore, MD, USA
Philip R Cunningham, PhD
Wayne State University, Detroit, MI, USA
Sunanda Ghosh Dastindar, PhD
Associate Director, Department of Pharmacology, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon, Haryana, India
Jeffrey Field, PhD
University of Pennsylvania, Philadelphia, PA, USA
Ravi Iyengar, PhD
Mount Sinai School of Medicine, New York, NY, USA
Salvatore D Lepore, PhD
Florida Atlantic University, Boca Raton, FL, USA
David D McPherson, MD
The University of Texas, Houston, TX, USA
Jason D Morrow, MD
Vanderbilt University, Nashville, TN, USA
Dale G Nagle, PhD
University of Mississippi, University, MS, USA
Philippe Taupin, PhD
National Neuroscience Institute, National University of Singapore, Singapore
Peter J Tonge, PhD
Stony Brook University, Stony Brook, NY, USA
Robert Vassar, PhD
Northwestern University, Chicago, IL, USA
Alan S Verkman, MD, PhD
University of California, San Francisco, CA, USA
Danny Winder, PhD
Vanderbilt University, Nashville, TN, USA
Copyright © 2011 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)
